The ARPC5L Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the A-549 human lung adenocarcinoma cell line through targeted disruption of the ARPC5L gene. This knockout product provides a genetically heterogeneous pool of cells with loss-of-function mutations in ARPC5L, enabling functional studies of this critical actin nucleation factor in a physiologically relevant epithelial context. The polyclonal nature of the population captures the diversity of CRISPR/Cas9-induced editing outcomes without selection for a single clone, making it suitable for experiments where population-level phenotypes are of primary interest, such as migration, invasion, and cytoskeletal organization assays.
The A-549 host cell line is an adherent epithelial cell line derived from a human lung adenocarcinoma and serves as a widely used model of alveolar type II epithelium. These cells harbor an activating KRAS G12S mutation, which drives oncogenic signaling pathways that converge on cytoskeletal remodeling and enhanced migratory potential. A-549 cells are extensively employed in cancer biology to investigate the molecular mechanisms of lung adenocarcinoma progression, metastasis, and drug resistance. Their well-characterized genetic background and robust growth in culture make them a reliable platform for generating gene-edited derivatives to dissect pathways governing cytoskeletal dynamics and cell motility.
ARPC5L encodes a subunit of the Arp2/3 complex, a seven-protein assembly that nucleates branched actin filament networks essential for lamellipodia formation, cell migration, endocytosis, and phagocytosis. This subunit is regulated downstream of the Rho-family GTPases RAC1 and CDC42, which activate nucleation-promoting factors of the WAS/WAVE family, including WAVE2. Upon activation, WAVE proteins recruit the Arp2/3 complex to sites of actin polymerization, where ARPC5L, together with other subunits such as ARP2, ARP3, ACTR2, and ACTR3, facilitates the conversion of globular G-actin into filamentous F-actin. The resulting branched networks generate the force required for membrane protrusion and directed cell movement. ARPC5L also interacts with cortactin, an additional regulator that stabilizes Arp2/3-mediated actin branch points.
Disruption of ARPC5L in A-549 cells directly compromises the functional integrity of the Arp2/3 complex, impairing the formation of branched actin structures and consequently reducing lamellipodia-driven migration and invasion. Given that A-549 cells are derived from a metastatic carcinoma and exhibit enhanced motility linked to KRAS signaling, this knockout model offers a powerful system to dissect the contribution of actin dynamics to lung adenocarcinoma invasiveness. It enables investigation of whether ARPC5L-mediated actin nucleation represents a rate-limiting step in the metastatic cascade and whether its loss creates vulnerabilities that can be exploited therapeutically.
This polyclonal ARPC5L knockout cell population is ideally suited for a broad range of functional assays. Western blotting can confirm ARPC5L protein depletion, while phalloidin staining of F-actin visualizes alterations in cytoskeletal architecture. Transwell migration and invasion assays quantitatively assess the impact on cell motility, and wound healing assays provide complementary readouts of collective cell migration. Proliferation assays can evaluate whether ARPC5L loss affects cell growth independently of migration defects. Transcriptomic analysis via RNA-seq may reveal compensatory transcriptional programs activated in response to actin remodeling impairment. Applications include mechanistic studies of actin regulation in lung cancer, screening for small molecules that target the migratory machinery, and examining the role of the Arp2/3 complex in endocytic trafficking within alveolar epithelial cells. For further details or to discuss custom applications, please contact Ascent Research.
